CA3054972A1 - Use of vitamin composition in preparing drug for preventing, treating, or delaying alzheimer's disease - Google Patents

Use of vitamin composition in preparing drug for preventing, treating, or delaying alzheimer's disease Download PDF

Info

Publication number
CA3054972A1
CA3054972A1 CA3054972A CA3054972A CA3054972A1 CA 3054972 A1 CA3054972 A1 CA 3054972A1 CA 3054972 A CA3054972 A CA 3054972A CA 3054972 A CA3054972 A CA 3054972A CA 3054972 A1 CA3054972 A1 CA 3054972A1
Authority
CA
Canada
Prior art keywords
vitamin
vitamins
composition
parts
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3054972A
Other languages
English (en)
French (fr)
Inventor
Mingdong Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zensun Shanghai Science and Technology Ltd
Original Assignee
Zensun Shanghai Science and Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zensun Shanghai Science and Technology Ltd filed Critical Zensun Shanghai Science and Technology Ltd
Publication of CA3054972A1 publication Critical patent/CA3054972A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA3054972A 2017-03-07 2018-02-24 Use of vitamin composition in preparing drug for preventing, treating, or delaying alzheimer's disease Abandoned CA3054972A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710131111.X 2017-03-07
CN201710131111.XA CN108567792A (zh) 2017-03-07 2017-03-07 一种治疗阿尔茨海默病的复合维生素组合物
PCT/CN2018/077107 WO2018161808A1 (zh) 2017-03-07 2018-02-24 维生素组合物在制备用于预防、治疗或延迟阿尔茨海默病的药物中的用途

Publications (1)

Publication Number Publication Date
CA3054972A1 true CA3054972A1 (en) 2018-09-13

Family

ID=63448062

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3054972A Abandoned CA3054972A1 (en) 2017-03-07 2018-02-24 Use of vitamin composition in preparing drug for preventing, treating, or delaying alzheimer's disease

Country Status (9)

Country Link
US (2) US11464797B2 (enExample)
EP (2) EP4461361A3 (enExample)
JP (3) JP7169285B2 (enExample)
CN (2) CN108567792A (enExample)
AU (2) AU2018229920B2 (enExample)
BR (1) BR112019018652A2 (enExample)
CA (1) CA3054972A1 (enExample)
ES (1) ES2989651T3 (enExample)
WO (1) WO2018161808A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114710952A (zh) * 2019-08-02 2022-07-05 上海日馨医药科技股份有限公司 Tpk作为靶点在阿尔茨海默病的应用
KR102275981B1 (ko) * 2020-03-31 2021-07-13 고려은단주식회사 섬쑥부쟁이 추출물과 비타민 b 복합체의 혼합물을 포함하는 인지기능 개선용 조성물
US20250381216A1 (en) * 2022-06-22 2025-12-18 Gen-Ichiro Soma Prophylactic drug and therapeutic drug for diabetes-associated dementia
CN119055674B (zh) * 2024-11-06 2025-02-18 中国医学科学院北京协和医院 一种可改善认知的组合物及其在阿尔茨海默病防治中的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5626884A (en) 1995-08-18 1997-05-06 Lockett; Curtis G. Treatment of sickle cell disease
WO1999064022A1 (en) 1998-06-10 1999-12-16 Crum Albert B Prophylactic and therapeutic nutritional supplement for creation/maintenance of health-protective intestinal microflora and enhancement of the immune system
AU2003218319A1 (en) 2002-03-22 2003-10-13 Doc's Guide, Inc. Multivitamin and mineral nutritional supplement
JP2004231585A (ja) * 2002-12-05 2004-08-19 Fancl Corp 生体内ホモシステインレベル低減用および上昇抑制用組成物
CA2583972A1 (en) 2004-10-14 2006-10-19 Adventures Plus Pty Ltd A method for the treatment of gastrointestinal and other disorders with an admixture of vitamins and minerals
US20110275591A1 (en) * 2004-12-01 2011-11-10 Concourse Health Sciences Llc Cocktail for modulation of alzheimer's disease
US20060148727A1 (en) * 2004-12-01 2006-07-06 Curt Hendrix Folate based composition for neurological and cognitive applications
MX2010000224A (es) * 2007-06-26 2010-05-03 Nutricia Nv Mejoramiento de la memoria en individuos con mini-examen de estado mental de 24-26.
US9763989B2 (en) * 2007-08-03 2017-09-19 Shaklee Corporation Nutritional supplement system
JP4206428B1 (ja) * 2008-06-09 2009-01-14 正樹 今川 認知症を処置するための組成物及びその利用
KR20110004691A (ko) * 2009-07-08 2011-01-14 대한민국(농촌진흥청장) 뇌기능 개선효과를 가지는 붉나무 추출물을 포함하는 약학조성물 및 건강식품조성물
WO2011121150A1 (es) * 2010-03-31 2011-10-06 Vegenat, S.A. Producto alimenticio enteral u oral especialmente destinado para la nutrición, prevención y mejora de alteraciones neurológicas, neurodegenerativas o trastornos cognitivos
JP2013526865A (ja) * 2010-05-13 2013-06-27 ニトロメガ コーポレーション ニトロ脂肪酸、神経保護および／または認識減退の抑制
JP2013532661A (ja) 2010-07-22 2013-08-19 リベン ファーマシューティカルズ インコーポレイテッド 磁気双極子安定化溶液の使用を含む疾患を処置または改善する方法および行動を向上させる方法
KR20130015932A (ko) * 2011-08-05 2013-02-14 연세대학교 산학협력단 저용량의 치아졸리딘다이온을 포함하는 알츠하이머 병 치료용 약학조성물
WO2013066151A1 (en) 2011-10-31 2013-05-10 N.V. Nutricia Improving recognition
CN104144691A (zh) * 2012-03-02 2014-11-12 N·V·努特里奇亚 改善功能突触连通性的方法
WO2014025905A1 (en) * 2012-08-07 2014-02-13 Buck Institute For Research On Aging Multi-component formulation for improving neurological function
US10894062B2 (en) * 2012-08-10 2021-01-19 Aquavit Pharmaceuticals, Inc. Vitamin supplement compositions for injection
CN104337813A (zh) 2013-07-23 2015-02-11 上海泽生科技开发有限公司 使用维生素b组合物促进胃肠系统动力的方法
CN104256652A (zh) 2014-10-08 2015-01-07 李明刚 一种口服复合维生素纳米脂质体
CN104922164B (zh) 2014-12-12 2020-06-02 中国医科大学 一种治疗阿尔茨海默病的药物复合制剂
CN106265696A (zh) * 2015-06-12 2017-01-04 上海泽生科技开发有限公司 使用复合维生素b、c组合物促进胃肠系统动力的方法
CN104856048A (zh) 2015-06-18 2015-08-26 安徽医联大成医药科技有限公司 一种促进肠胃蠕动的食品配方及其制备方法
CN108079008A (zh) * 2016-11-23 2018-05-29 上海泽生科技开发股份有限公司 促进胃肠系统动力的复合维生素组合物

Also Published As

Publication number Publication date
JP2020509072A (ja) 2020-03-26
EP3593805A1 (en) 2020-01-15
US20200030358A1 (en) 2020-01-30
EP4461361A3 (en) 2025-01-01
US20230248756A1 (en) 2023-08-10
ES2989651T3 (es) 2024-11-27
CN110520135A (zh) 2019-11-29
US11464797B2 (en) 2022-10-11
AU2018229920A1 (en) 2019-10-03
JP2023011769A (ja) 2023-01-24
EP4461361A2 (en) 2024-11-13
AU2018229920B2 (en) 2024-02-08
JP7169285B2 (ja) 2022-11-10
AU2024202678A1 (en) 2024-05-16
EP3593805A4 (en) 2020-10-07
WO2018161808A1 (zh) 2018-09-13
JP2025024089A (ja) 2025-02-19
EP3593805B1 (en) 2024-07-24
BR112019018652A2 (pt) 2020-04-07
CN108567792A (zh) 2018-09-25

Similar Documents

Publication Publication Date Title
US20230248756A1 (en) Use of vitamin composition in preparing drug for preventing, treating, or delaying alzheimer's disease
Marques et al. Creatine as a neuroprotector: an actor that can play many parts
Zhang et al. Salidroside attenuates beta amyloid-induced cognitive deficits via modulating oxidative stress and inflammatory mediators in rat hippocampus
Geisler et al. DNP, mitochondrial uncoupling, and neuroprotection: A little dab'll do ya
Pei et al. Directly and indirectly targeting the glycine modulatory site to modulate NMDA receptor function to address unmet medical needs of patients with schizophrenia
CA2766282C (en) Inhibitors of carnitin-palmitoyl-transferase-1 for the treatment and prevention of disorders caused by delipidation of neural tissue
Ishola et al. Prevention and reversal of ketamine-induced experimental psychosis in mice by the neuroactive flavonoid, hesperidin: The role of oxidative and cholinergic mechanisms
JP5066756B2 (ja) 脳機能障害予防・改善用の薬剤及び飲食物
Al-Jarrah et al. Endurance exercise training protects against the upregulation of nitric oxide in the striatum of MPTP/probenecid mouse model of Parkinson's disease
AU2002250942A1 (en) Compositions of biochemical compounds involved in bioenergy metabolism of cells
EP1368017A2 (en) Compositions of biochemical compounds involved in bioenergy metabolism of cells and method of use
Li et al. Theacrine, a purine alkaloid derived from Camellia assamica var. kucha, ameliorates impairments in learning and memory caused by restraint-induced central fatigue
Liu et al. Insights on neuropharmacological benefits and risks: Aconitum carmichaelii Debx.
Majolo et al. Recent Drugs Tested in Clinical Trials for Alzheimer´ s and Parkinson´ s Diseases Treatment: Current Approaches in Tracking New Drugs
EP2470213A1 (en) Composition for treatment of neurodegenerative diseases or disorders, method and use comprising electromagnetically irradiated yeast
Kahale et al. To determine the Effect of Berberine on 6-OHDA induced memory impairment in Parkinson’s disease in rodents
CN104582730B (zh) 一种提高线粒体代谢机能的方法及应用
CN110193019B (zh) 具有抗抑郁与抗老年痴呆症功效的组合物及其应用
Archer et al. Pharmacogenomics and personalized medicine in Parkinsonism
CN121370888A (zh) 一种用于治疗代谢综合征的内源性小分子代谢物
Zhang et al. No effect of pyrroloquinoline quinone on mouse body weight and energy metabolism with the concomitant increase in mitochondrial biogenesis and antioxidant ability
Atabilen et al. Could the ketogenic diet offer hope in management of neurological diseases?
Agrawal et al. Evaluation of Hordenine’s Therapeutic Potential in Alzheimer’s Disease-induced Cognitive and Oxidative Impairments
Moreira Inhibiting COMT in a mouse model of Parkinson's disease: a trial of Tolcapone in VMAT2-deficient mice
WO2022216543A1 (en) Enantiomer selective action on neurotransmission

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220824